ArticleCancer immunology, immunotherapy : CII2012

Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells.

Stefanie J Mandl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.